Shigru Patra Arka preparation and clinical trial in Allergic conjuntivitis

Evaluate the effect of Eyedrop Shigrupatra Arka in Simple Allergic Conjunctivitis- Randomised Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061729

Enrollment

Registered

2024-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H109- Unspecified conjunctivitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients presenting with simple allergic conjunctivitis with established signs and symptoms of itching, redness, oedema and watering with eosiniphilia will be subjected for detailed anterior segment examination using slit lamp biomicroscope for diagnosis 2 Either gender and socioeconomic status

Exclusion criteria

Exclusion criteria: 1 Patient suffering from other forms of allergic conjunctivitis like keratoconjunctivitis sicca, atropic keratoconjunctivitis, giant papillary conjunctivitis, drug or material senstivity, perennial allergic conjunctivitis etc. 2 Patients having severe conditions of ocular surface disorders 3 Patients having complicated eye diseases like Trachoma, Trichiasis, Steven Johnson syndrome, Synechiae etc will be excluded 4 Patient suffering from bacterial, viral, chlamydial, parasitic and all other types of conjunctivitis (contagious & non contagious) 5 Patients suffering from corneal ulcers, opacities, trauma, foreign bodies, OSD, etc 6 Conjunctival epitheliopathies like Pterygium, Pseudo-pterygium, Tumours, Retention cysts 7 Diagnosed cases of Glaucoma, retinopathies, optic neuritis, dry eye and who are under long term topical ocular drug therapies for any ophthalmic infective conditions 8 Extremely debilitated patients, pregnant ladies those who are working with on- screen professions 9 Specific systemic disorders like Renal pathologies, Uncontrolled Diabetes, Hypertension, and Hyperlipidaemia, Cardiovascular diseases, etc

Design outcomes

Primary

Measure	Time frame
The results of reduction in signs and symptoms of itching, redness, watering and oedema by Eyedrop Shigrupatra Arka and Eyedrop Naphazoline hydrochloride (0.025%) with Pheniramine maleate (0.3%) are comparable.Timepoint: Day 01(before treatment), Day 15(during treatment), Day 22 (after treatment), Day 36 (follow up)	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Arunkumar B Biradar

KAHERs Shri BMK Ayurveda Mahavidyalaya, Shahapur, BELAGAVI, Karnataka, INDIA

arunkumar.biradar@gmail.com9964064955

Outcome results